Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
979
datasets available to search
ShareScore release 0.9.0
Dataset results
979 results for “HR”
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-re
ClinicalTrials.gov study NCT05128773. IPD Sharing: YES. Countries: 2. Publications: 0.
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
ClinicalTrials.gov study NCT02152943. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
ClinicalTrials.gov study NCT05346224. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
ClinicalTrials.gov study NCT04263298. IPD Sharing: NO. Countries: 1. Publications: 0.
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Riboci
ClinicalTrials.gov study NCT06311383. IPD Sharing: NO. Countries: 1. Publications: 1.
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2
ClinicalTrials.gov study NCT03906669. IPD Sharing: NO. Countries: 1. Publications: 2.
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
ClinicalTrials.gov study NCT06344780. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
ClinicalTrials.gov study NCT05212454. IPD Sharing: NO. Countries: 1. Publications: 7.
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
ClinicalTrials.gov study NCT02732119. IPD Sharing: YES. Countries: 1. Publications: 0.
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT05054751. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
ClinicalTrials.gov study NCT05840211. IPD Sharing: NO. Countries: 28. Publications: 1.
HR-EGG in Medically Refractory Gastroparesis
ClinicalTrials.gov study NCT05789511. IPD Sharing: UNDECIDED. Countries: 1. Publications: 11.
24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination
ClinicalTrials.gov study NCT00972257. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT02990845. IPD Sharing: Not stated. Countries: 1. Publications: 1.
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
ClinicalTrials.gov study NCT06001762. IPD Sharing: YES. Countries: 1. Publications: 0.
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
ClinicalTrials.gov study NCT04895761. IPD Sharing: NO. Countries: 1. Publications: 22.
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
ClinicalTrials.gov study NCT05455619. IPD Sharing: NO. Countries: 1. Publications: 2.
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
ClinicalTrials.gov study NCT03925350. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Sub-Occipital MIT With and Without HR Agonist Contraction of Hamstrings in Neck Pain Patients With Hamstring Tightness
ClinicalTrials.gov study NCT05353075. IPD Sharing: NO. Countries: 1. Publications: 10.
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer
ClinicalTrials.gov study NCT02404844. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.